Kyverna appoints Andrew Miller and Sravan Emany to Board; Spiegelman resigns

Kyverna Therapeutics, Inc.

Andrew Miller (Karuna founder) appointed Class III director; granted option valued at $262k and RSUs valued at $87.5k.
Sravan Emany (Beam CFO) appointed Class I director and Audit Committee Chair; receives same initial equity awards.
Daniel Spiegelman resigned Feb 24, no disagreement with company operations, policies or practices.
Miller brings drug development experience from Karuna's $14B BMS acquisition; Emany adds capital markets and rare disease expertise.
Both directors receive cash comp: $40k board retainer plus committee fees; equity vests over 3 years with full acceleration on change of control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.